Thompson Siegel & Walmsley LLC Increases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thompson Siegel & Walmsley LLC increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 8.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 781,215 shares of the specialty pharmaceutical company’s stock after buying an additional 59,685 shares during the quarter. Jazz Pharmaceuticals comprises about 1.3% of Thompson Siegel & Walmsley LLC’s investment portfolio, making the stock its 14th biggest position. Thompson Siegel & Walmsley LLC owned 1.27% of Jazz Pharmaceuticals worth $87,035,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Foundry Partners LLC lifted its holdings in shares of Jazz Pharmaceuticals by 10.9% during the 3rd quarter. Foundry Partners LLC now owns 3,362 shares of the specialty pharmaceutical company’s stock valued at $375,000 after acquiring an additional 331 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 3.9% during the third quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company’s stock worth $1,072,000 after purchasing an additional 364 shares in the last quarter. Swiss National Bank lifted its stake in shares of Jazz Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 117,000 shares of the specialty pharmaceutical company’s stock worth $13,035,000 after purchasing an additional 400 shares in the last quarter. Natixis Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 7.6% in the third quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock worth $2,544,000 after buying an additional 1,603 shares during the period. Finally, CIBC Asset Management Inc acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $209,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 2.1 %

NASDAQ:JAZZ opened at $119.24 on Thursday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The business has a 50 day simple moving average of $112.64 and a 200 day simple moving average of $110.45. The firm has a market capitalization of $7.21 billion, a P/E ratio of 16.79, a P/E/G ratio of 0.98 and a beta of 0.57.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock valued at $720,160 in the last ninety days. Company insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on JAZZ. JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Royal Bank of Canada upped their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, October 23rd. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.53.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.